| INTRODUCTION
Proton-pump inhibitors (PPIs) are commonly and increasingly used among older population, 1-3 although they have been associated with several serious adverse events, such as fractures and pneumonia. [4] [5] [6] Indications for PPI use among older persons are dyspepsia, gastroesophageal reflux disease and peptic ulcer, but due to gastro-protective properties they are also co-prescribed with nonsteroidal antiinflammatory drugs and corticosteroids. 7, 8 Hip fractures are a major health concern among older persons with Alzheimer's disease, and Alzheimer's disease itself seems to be a risk factor for falling, and consequently, hip fractures. 9, 10 In addition, older persons with Alzheimer's disease usually use many concomitant drugs for several diseases, which both are fall risk increasing factors.
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Association between PPI use and risk of fractures remains unclear. Several previous studies have found association between PPI use and an increased risk of hip fracture [12] [13] [14] [15] [16] but there are also studies which did not find an association. [17] [18] [19] According to a novel meta-analysis, the risk seems to be modestly increased (RR = 1.26;
95% CI 1.16-1.36), albeit the studies are heterogeneous. 6 It has been supposed that PPI use lead to bone loss and fractures by reducing calcium absorption. 18 However, some studies have reported that PPI use has no effects on bone structure. [20] [21] [22] Other mechanisms suggested are myopathy 23 or vitamin B12 deficiency 24 leading to injurious falls and fractures. 25 To our knowledge, no previous study has investigated whether current use, duration of current use, past use or cumulative PPI use are associated with risk of hip fracture among persons with Alzheimer's disease. Thus, the objective of this study was to investigate whether there is an association between longterm PPI use and risk of hip fractures among community-dwelling persons with clinically verified diagnosis of Alzheimer's disease.
| MATERIALS AND METHODS

| Data source
In this study, the nationwide register-based MEDALZ (Medication use and Alzheimer's disease) data were utilised. 
| Study population
This study was restricted to persons with incident hip fracture.
Persons with a hip fracture before the diagnosis of Alzheimer's disease (n = 3714) were excluded (Figure 1) 
| Statistical analysis
Conditional logistic regression model (by taking into account the matched design) was used to investigate whether current, past, or According to Finnish legislation, an approval from ethics committee was not needed, because the study persons stayed unidentified and were not contacted.
| RESULTS
Mean age of cases was 84.1 (SD 6.0) and controls 84.0 (SD 5.8)
years, and most of the study population (75%) were women (Table 1) . Previous fracture was more common among cases (35%) compared to controls (20%). Cases were more commonly using antipsychotics, antidepressants, opioids and benzodiazepines and related drugs compared with controls. Acetylcholine esterase inhibitors were more commonly used by controls than cases.
Mean time since Alzheimer's disease diagnoses to index date was 849 (SD 611) days in cases and 847 (SD 612) days in controls.
Almost half of the cases (2321; 48%) and controls (9066; 47%) had used PPI during 10 years before the index date ( Pantoprazole was the most commonly used PPI at the index date (Table 3 ). There were no significant differences between PPI drug substances and associated risk of hip fracture after adjusting for confounders.
Among current users of PPI (N = 4247), 79% were women compared to 75% of those who did not currently use PPI (N = 19 806). Cardiovascular diseases were more common among current PPI users (59%) than non-users (51%). Current PPI users used oral corticosteroids (34%), bisphosphonate (27%), antidepressants (39%), benzodiazepines and related drugs (36%), opioids (13%) and H2-blockers (34%) more frequently than non-users of PPI (among non-users prevalences were 20%, 16%, 22%, 23%, 5%
and 18%, respectively). deficiency, could increase the fracture risk during less than 1 year of use. [23] [24] [25] 38, 40 In addition, the evidence of these mechanisms is contradictory. 17, 20 Our results are in contrast with two studies that found an Long-term use ≥1 year: crude OR 1.12 (95% CI 1.00-1.25), P value 0.058; adjusted OR 1.00 (95% CI 0.89-1.13), P value 0.946. Our study found no differences between drug substances and risk of hip fracture. Three previous studies have reported differences between drug substances. 16, 42, 44 Two found an increased risk associated with omeprazole use 16, 42 compared to non-use of omeprazole, and one found no significant differences. 44 Psychotropic drugs, which have been previously shown to be associated with an increased risk of hip fractures [35] [36] [37] were more commonly used by persons with hip fracture than their controls. Consistent to previous studies, 41, 45 persons with hip fracture were more likely to have epilepsy or previous fracture or stroke, which are also risk factors for falling. 11 Opioids were used more commonly among hip fracture cases compared to controls, which indicates that pain was more prevalent among cases and may be one reason for falling and fracture. 
T A B L E 1 Differences between hip fracture cases and controls
